|
|
||||||||||
|
J Am Coll Cardiol, 2002; 40:93-99 © 2002 by the American College of Cardiology Foundation |




* Atrial Arrhythmia Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Medtronic Inc., Minneapolis, Minnesota, USA
Cedars-Sinai Medical Center, Los Angeles, California, USA
Iowa Heart Center, Des Moines, Iowa, USA
Manuscript received October 11, 2001; revised manuscript received March 27, 2002, accepted April 5, 2002.
* Reprint requests and correspondence: Dr. David Schwartzman, Cardiovascular Institute, Presbyterian University Hospital, B535, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213-2582, USA.
schwartzmand{at}msx.upmc.edu
OBJECTIVES: We sought to gain insights into the early recurrence of atrial fibrillation (ERAF) after cardioversion shocks delivered by permanently implanted rhythm management systems.
BACKGROUND: Several reports have characterized ERAF, but these reports used a limited definition and did not evaluate an association between clinical or device variables and ERAF.
METHODS: A total of 144 patients with recurrent, drug-resistant, symptomatic atrial fibrillation (AF) underwent implantation of an atrial rhythm management system (Medtronic Jewel AF, Model 7250, Minneapolis, Minnesota). The device was programmed to deliver cardioversion shocks automatically and/or on patient command. The incidence of ERAF was evaluated after 1,092 successful shocks among 97 patients. Three different ERAF definitions were used: recurrence within 1 min, 1 h or 1 day. Multiple clinical and device variables were assessed for their relationship with ERAF.
RESULTS: The per-patient incidences of ERAF were 44%, 61% and 70% for ERAF within 1 min, 1 h and 1 day, respectively. The per-episode incidences of ERAF were 17%, 30% and 43% for ERAF within 1 min, 1 h and 1 day, respectively. Variables that were independently associated with ERAF included AF duration <3 h before termination, more than one shock required to cardiovert and the absence of a previous myocardial infarction. The most potent variable was AF duration <3 h, associated with a threefold increase in the incidence of ERAF.
CONCLUSIONS: Recurrence of AF early after ambulatory shock cardioversion is common. In this retrospective study, both clinical and device variables were predictive.
| ||||||||||||||||
This article has been cited by other articles:
![]() |
D. Schwartzman, M. N. Harvey, R. H. Hoyt, J. L. Koehler, M. R. Ujhelyi, and D. E. Euler Utility of adjunctive single oral bolus propafenone therapy in patients with atrial defibrillators. Europace, March 1, 2006; 8(3): 211 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R.J. Mitchell 'The patient takes charge' -- long term use of the atrial defibrillator Eur. Heart J., December 1, 2003; 24(23): 2075 - 2076. [Full Text] [PDF] |
||||
![]() |
J.C. Geller, S. Reek, C. Timmermans, T. Kayser, H.-F. Tse, C. Wolpert, W. Jung, A.J. Camm, C.-P. Lau, H. J.J. Wellens, et al. Treatment of atrial fibrillation with an implantable atrial defibrillator -- long term results Eur. Heart J., December 1, 2003; 24(23): 2083 - 2089. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |